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HIV-1 infection currently cannot be cured because the virus persists as integrated proviral DNA
in long-lived cells despite years of suppressive antiretroviral therapy (ART). To characterize estab-
lishment, turnover, and evolution of viral DNA reservoirs we deep-sequenced the p17gag region of
the HIV-1 genome from samples obtained from 10 patients after 3-18 years of suppressive ART.
For each of these patients, whole genome deep-sequencing data of HIV-1 RNA populations before
onset of ART were available from 6-12 longitudinal plasma samples spanning 5-8 years of untreated
infection. This enabled a detailed analysis of the dynamics and origin of proviral DNA during
ART. A median of 14% (range 0-42%) of the p17gag DNA sequences were overtly defective due to
G-to-A hypermutation. The remaining sequences were remarkably similar to previously observed
RNA sequences and showed no evidence of evolution over many years of suppressive ART. Most
sequences from the DNA reservoirs were very similar to viruses actively replicating in plasma (RNA
sequences) shortly before start of ART. The results do not support persistent HIV-1 replication as
a mechanism to maintain the HIV-1 reservoir during suppressive therapy. Rather, the data indicate
that viral DNA variants are turning over as long as patients are untreated and that suppressive
ART halts this turnover.
Introduction
Combination antiretroviral therapy (ART) has had a
dramatic effect on the morbidity and mortality of hu-
man immunodeficiency virus type 1 (HIV-1) infection.
Even though ART is very effective in suppressing ac-
tive virus replication, it cannot eradicate the infection
because HIV-1 persists as integrated proviral DNA in
long-lived cells that constitute a virus reservoir. Latently
infected resting memory CD4+ T-lymphocytes (memory
CD4 cells) represent the most solidly documented HIV-1
reservoir [1–3]. Thus, a small fraction of memory CD4
cells have fully functional integrated HIV-1 proviruses.
These cells do not produce virus when they are in a rest-
ing state, but can be induced to produce virus upon ac-
tivation in vitro and in vivo [1–4].
Because of their importance for HIV-1 cure efforts,
many methods to quantify the HIV-1 reservoirs have
been developed. The quantitative virus outgrowth assay
(QVOA) represents the “gold standard” [4–6], but this
assay underestimates the true size of the functional reser-
voir due to incomplete induction by PHA stimulation.
Ho et al.[7] showed that the functional HIV-1 reservoir
may be 60-fold larger than originally estimated. PCR
based assays are also commonly used for quantifying the
HIV-1 reservoir, but these assays overestimate the size
of the functional reservoir because they cannot distin-
guish between replication-competent and defective viral
genomes. Quantification of the HIV-1 reservoir by PCR-
based methods typically give at least 100-fold higher
numbers that the QVOA because of defective proviruses
[4–6]. Many defective proviruses have large internal dele-
tions [7, 8]. Defective proviruses are also the result of
APOBEC editing, which induces G-to-A hypermutation
[9–11].
The HIV-1 reservoir is established early during pri-
mary infection and is remarkably stable in both quanti-
tative and qualitative terms. Early ART reduces the size
and the genetic complexity of the reservoir [12–15]. Sili-
ciano et al.[16] documented a half-life of 44 months for
latently infected cells capable of producing replication-
competent virus in the QVOA. Similarly, HIV-1 DNA
levels and genetic compositions are very stable in patients
on long-term suppressive ART [5, 13, 17–21]. Most stud-
ies indicate that the HIV-1 reservoir is maintained by the
physiological homeostasis of CD4 memory that in part
involves occasional expansions and contractions of indi-
vidual CD4 cell clones [5, 12, 22]. However, some stud-
ies have suggested that persistent virus replication may
be an important contributor to the maintenance of the
HIV-1 reservoir [23, 24]. In particular, Lorenzo-Redondo
et al.[25] recently reported evidence of rapid HIV-1 evo-
lution in lymphoid tissue reservoirs.
Despite their significance for HIV-1 cure efforts rel-
atively little is known about the establishment and
turnover of the HIV-1 reservoir before start of ART. In
this study we have characterized how HIV-1 DNA reser-
voirs are established and maintained in 10 patients. Evo-
lution of HIV-1 in these patients during 5-8 years prior to
ART had been characterized in a recent study by Zanini
et al.[26] by whole genome deep-sequencing. The patients
were selected to later have gone on to many years of fully
suppressive ART. We now sequenced HIV-1 DNA from
peripheral blood mononuclear cells (PBMCs) and com-
pared these reservoir sequences to replicating HIV popu-
lations prior to ART. The timing of all available samples
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Figure 1: Sampling times before and after start of treatment.
For each study participant, the thick grey bar indicates the
period of untreated HIV-1 replication, while circles mark the
collection times of RNA samples used for whole genome deep
sequencing [26]. The collection dates of PBMC samples used
for p17gag deep sequencing of integrated provirus are indi-
cated by triangles and squares. All times are relative to start
of treatment.
relative to start of treatment is summarized in Fig. 1.
We found that HIV-1 DNA populations remained ge-
netically stable for up to 18 years after start of suppres-
sive ART, which provides evidence against viral evolution
and replication as a mechanisms to maintain HIV-1 reser-
voirs. Furthermore, we found that variants replicating
shortly before start of therapy were overrepresented in
the HIV-1 DNA reservoirs indicating that proviral HIV-
1 variants were turning over as long as the patients were
untreated.
Results
Patients and samples
The study included 10 HIV-1 infected patients who
were diagnosed in Sweden between 1990 and 2003. The
patients were selected on the following criteria: 1) A rel-
atively well-defined time of infection; 2) Treatment-naive
for a minimum of 5 years; and 3) Thereafter gone on
to suppressive ART (plasma HIV-1 RNA levels continu-
ously <50 copies/ml) for a minimum of 2 years. In a re-
cent study we performed whole-genome deep sequencing
of replicating HIV-1 RNA populations in 9 of the 10 pa-
tients covering the time period before they started ART
(6-12 longitudinal plasma samples per patient spanning
5-8 years) [26]. Here we included plasma RNA sequences
from the tenth patient. Patient characteristics are sum-
marized in Fig. 1 and Table 1.
For the present study we have obtained sequence data
from HIV-1 DNA in viral reservoirs by deep sequencing of
the p17gag region of the HIV-1 genome in DNA prepared
from PBMC. Patient characteristics are summarized in
Table 1. Longitudinal PBMC samples (1-3 samples per
patient spanning up to 2.6 years) were obtained obtained
3 - 18 years after start of suppressive ART (Table 1). We
define viral DNA reservoirs as HIV p17gag sequences that
were still present in PBMC after a minimum of 2 years
of suppressive ART. The HIV-1 DNA template numbers
were quantified by limiting dilution. Identical p17gag
sequences were merged into haplotypes while preserving
their abundance. Minor haplotypes were merged with
major haplotypes if they differed by only one mutation
(see Materials and Methods). Processed sequence data
will be made available at hiv.tuebingen.mpg.de. Raw
sequencing reads from all HIV-1 DNA samples have been
deposited in the European Nucleotide archive and will
be available under study accession number PRJEB13841
(sample accession numbers ERS1138001-ERS1138025).
Proviral DNA sequences reflect pretreatment RNA
sequences
The HIV-1 DNA sequences recapitulate the diversity
observed in RNA sequences before treatment, often with
exact sequence matches, see Fig. 2 and Fig. S3. While we
observed large variations in the abundance of haplotypes
with sequence read frequencies varying between 0.1% and
50% (see Fig. S1), the close match between RNA and
DNA sequences confirms that we characterized proviral
diversity in a specific and sensitive manner. Variation
in haplotype abundance likely reflects clonal expansions
[5, 13], independent integrations of identical sequences,
and resampling of the same original DNA templates dur-
ing sequencing. The exact contribution by these distinct
mechanisms is difficult dissect in our sequence data.
The estimated number of HIV DNA templates, the
number of distinct haplotypes observed, and the fraction
of haplotypes seen in multiple samples are given in Table
S1. We typically recapture one third (median 0.29) of
haplotypes observed at a frequency above 1% in another
sample from the same patient.
Hypermutated sequences are frequent in HIV-1
reservoirs
We found that a substantial proportion (median 14%;
range 0-42%) of the p17gag DNA sequences from the vi-
ral reservoirs were hypermutated and therefore replica-
tion incompetent (see Fig. S2), which is consistent with
other reports [5, 6, 10, 13]. A small proportion of se-
quences had stop codons not obviously due to G-to-A
hypermutation (average 3%, range 0-12%) . It is likely
that a proportion of sequences without overt inactivat-
ing mutations were also replication incompetent due to
mutations or deletions outside of p17gag.
Hypermutation in the HIV-1 DNA sequences compli-
cates comparison with non-defective DNA and RNA se-
quences. For this reason we excluded hypermutated se-
quences from the main analyses, but we also performed
complementary analyses that included hypermutated se-
quences.
3Patient Gender Transmission Subtype Agea HIV RNA from plasma HIV DNA from PBMCs
# samples first/last since EDIb time on ARTb # templates
p1 F HET 01 AE 37 12 0.3 8.2 7.9/ 9.9/ 10.4 820/ 148/ 38
p2 M MSM B 32 6 0.2 5.5 6.9 75
p3 M MSM B 52 10 0.4 8.4 4.6/6.7/ 7.2 243/ 102/ 108
p5 M MSM B 38 7 0.4 5.9 4.0/ 6.3 180/ 72
p6 M HET C 31 7 0.2 7.0 3.0/ 5.0/ 5.5 115 /15/ nd
p7 M MSM B 31 11 6.3c 16.1 6.3/ 8.4/ 8.8 88/ 279/ 108
p8 M MSM B 35 7 0.2 6.0 8.4/ 10.6/ 10.9 180/ 55/ 175
p9 M MSM B 32 8 0.3 8.1 7.7/ 9.7/ 10.2 60/ 72/ 72
p10 M MSM B 34 9 0.1 6.2 16.2/ 18.3/ 18.6 249/ 116/ 51
p11 M MSM B 53 7 0.6 5.6 6.4/ 8.4/ 8.8 124/ 120/ 123
Table I: Summary of patient characteristics. a at diagnosis; b EDI: estimated date of infection; all times are given in
years; c sequencing failed in earlier samples due to low plasma HIV-1 RNA levels.
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Figure 2: Reconstructed phylogenetic trees of RNA sequences (circles) and DNA (blue squares and triangles) from two patients.
RNA sequences are colored by time since infection from yellow to red to black. Size of the symbols indicates the fraction of
reads represented by the node. The trees were build using the software FastTree (see methods) [27].
Lack of evidence of persistent replication in HIV-1
DNA reservoirs
It remains controversial whether or not HIV-1 reser-
voirs are maintained by persistent replication [5, 12, 20,
22–25]. We used the p17gag DNA sequences from vi-
ral reservoirs to search for evidence of sequence evolu-
tion, which would be expected to take place if the virus
was replicating. The p17gag DNA sequences from viral
reservoirs were obtained from 3.0 to 18.6 years after start
of suppressive ART. HIV-1 RNA sequences from plasma
samples obtained before start of therapy were used as
reference materials.
Root-to-tip distances for plasma RNA populations and
PBMC DNA populations were calculated relative to the
major RNA haplotype in the first plasma sample. Fig. 3
shows temporal changes of root-to-tip distances in HIV-
1 RNA and DNA populations obtained before and af-
ter start of suppressive ART, respectively. As previously
shown, plasma HIV-1 RNA populations obtained before
start of ART evolved at a relatively constant rate [26],
as evidenced by a steady increase of average root-to-tip
distances over time. In sharp contrast, HIV-1 DNA pop-
ulations obtained after 3 - 18 years of suppressive ther-
apy showed stable root-to-tip distances. Hypermutated
DNA sequences showed larger root-to-tip distances, but
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Figure 3: Root-to-tip distances. Plasma HIV-1 RNA sequences evolve steadily before start of ART, while no evolution is
observed in PBMC HIV-1 DNA sequences obtained after start of ART. The figure contains data on DNA sequence not classified
as hypermutants, the analogous figure for hypermutants in shown in Fig. S4. The error bars indicated the inter-quartile range
of the root to tip distance.
also these distances were stable over time (Fig. S4)
Table 2 shows the rate of evolution before and after
start of suppressive ART. Before start of therapy we ob-
served statistically significant evolution of plasma RNA
sequences with rates 1 to 4 × 10−3/year in all 10 pa-
tients. In contrast, no statistically significant evolution
was observed in DNA reservoirs during up to 18 years of
suppressive ART.
Collectively, our results do not provide support for per-
sistent HIV-1 replication as a mechanism to maintain the
HIV-1 reservoir during suppressive therapy.
Time for deposition of reservoir DNA sequences
To investigate when PBMC HIV-1 DNA variants had
been deposited the viral reservoirs we compared the on-
treatment PBMC DNA sequences with the longitudi-
nal pre-treatment plasma RNA sequences (Fig. 4 and
Fig. S5). For each p17gag DNA sequence, we determined
the RNA sample and haplotype that was the most likely
source. By this procedure, most proviral sequences were
assigned to the plasma samples closest to the start of
treatment (Fig. 4, panel A). The representation of RNA
haplotypes from earlier plasma samples dropped rapidly
over 1-2 years. However, sequences representing ear-
lier plasma sampling time points were also found as mi-
nor variants among the p17gag DNA sequences. Among
these minor variants, DNA sequences matching the vari-
patient RNA rate DNA rate
[year−1] p-value [year−1] p-value
p1 4.2× 10−3 < 10−6 1× 10−4 0.866
p2 3.3× 10−3 < 10−3 2× 10−4 –
p3 4.2× 10−3 < 10−6 0 1.0
p5 4.6× 10−3 < 10−3 1× 10−4 0.93
p6 1.3× 10−3 < 10−3 −6× 10−4 0.67
p7 1.4× 10−3 < 10−2 −8× 10−4 0.3
p8 3.0× 10−3 < 10−4 2× 10−5 0.94
p9 2.4× 10−3 < 10−4 3× 10−7 0.87
p10 3.5× 10−3 < 10−5 −1× 10−4 0.55
p11 1.1× 10−3 < 10−2 6× 10−5 0.6
Table II: Rates of evolution in plasma RNA and PBMC DNA
sequences obtained before start and after start of suppressive
ART, respectively.
ant dominating the first plasma samples obtained within
6 month after infection were overrepresented in some pa-
tients (Fig. 4, panel B). Thus, the proportion of DNA
sequences matching the initial plasma HIV-1 RNA hap-
lotype was 14%, 2.4%, 42%, <1%, and 6.9% in patients
2, 3, 6, 8 and 11, respectively.
The overrepresentation in the HIV-1 DNA reservoir
of viral variants that replicated shortly before start of
suppressive ART indicates that cells carrying defective
and non-defective proviral variants were turning over as
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Figure 4: Probable origin of sequences in the DNA
reservoir. Panel A shows the time difference between the
start of treatment and the RNA sample that is most likely
to have generated at sequence from the reservoir. A large
proportion of the reservoir DNA sequences are most closely
related to RNA sequences in the plasma samples obtained
during the last year before start of therapy. Panel B focuses on
DNA sequences resembling RNA sequences obtained during
the first two years after estimated time of infection. These
sequences represent a small fraction of all reads obtained and
are observed in 50% of patients only.
long as the patients were untreated and that suppressive
ART halted this turnover. The width of the peak in
Fig. 4A suggest a half-life on the order of one year.
Discussion
In this study we have investigated the composition
and turnover of HIV-1 DNA sequences in viral reser-
voirs in patients on long-term suppressive therapy. Reser-
voir HIV-1 DNA populations were remarkably stable and
showed no signs of ongoing replication. We also traced
when during the course of HIV infection viruses in the
the DNA reservoirs had been deposited and found that
they mainly derived from the last year(s) before start of
suppressive therapy.
Our study provides evidence against persistent HIV-
1 replication as a mechanism for maintenance of HIV-1
reservoirs during suppressive therapy. This is at vari-
ance with a recent report by Lorenzo-Redondo et al. [25]
and a few earlier reports [23, 24], but agrees with several
other earlier studies [5, 13, 17–21]. Lorenzo-Redondo et
al. [25] compared genetic diversity in samples HIV-1 RNA
in plasma at start of therapy with HIV-1 DNA sequences
obtained from blood and tissues at baseline, three and six
months after the start of treatment. They report a signal
of evolution between the different time points at an ex-
traordinary high rate (7.4−12×10−3 changes per site per
year) – about 5-fold higher than typically observed in gag
and pol of replicating RNA populations. This observa-
tion is incompatible with the lack of observable changes
in reservoir sequences over 20 times longer time intervals
reported here. Without longitudinal data on the evo-
lution of the HIV-1 population prior to treatment, the
nature of the change reported by Lorenzo-Redondo et
al. [25] is difficult to discern. One possible explanation
for the apparent conflict between the two studies could
be that after onset of therapy, short-lived cells that sam-
pled the most recent circulating virus populations start to
disappear, leaving longer-lived cells that sample deeper
into the history of the infection. This scenario would not
correspond to evolution, but quite oppositely a sampling
of earlier variants. Another difference is that Lorenzo-
Redondo et al. [25] investigated HIV-1 DNA sequences in
tissue as well as PBMC samples whereas we only stud-
ied PBMC samples. However, tissue and blood HIV-1
DNA variants should be well-mixed over the time frame
that we investigate [5, 13, 25]. Both Lorenzo-Redondo et
al. [25] and we studied DNA sequences in HIV-1 reser-
voirs, which are known to contain a high proportion of de-
fective virus. These proviruses serve as markers of T-cell
clones, rather than replication-competent virus. Hence
the absence of evolution or turnover of provirus that we
found does not exclude the possibility that there is repli-
cation and evolution of replication-competent virus in
reservoirs. However, if such replication exists, it happens
very low levels that do not contribute substantially to
the pool of proviral DNA in PBMCs. To enrich for repli-
cation competent and putatively evolving virus, QVOA
followed by sequencing of virus released into to super-
natants should performed, rather than sequencing of to-
tal HIV-1 DNA as done by Lorenzo-Redondo et al. [25],
us and others [10, 13, 20]. In agreement with our find-
ing of genetic stability in the DNA reservoirs Josefsson et
al. [13] and Stockenstrom et al. [5] have reported that de-
fective HIV-1 DNA integrants present during long-term
effective ART appear to be maintained by proliferation
and longevity of infected cells rather than by ongoing
viral replication.
Because we had access to detailed longitudinal data
on the evolution of the plasma HIV-1 RNA population
from time of infection to start of suppressive ART, we
could trace when during the course of untreated HIV-1
infection the viruses in the DNA reservoirs had been de-
posited. We found that a majority of variants in the HIV-
1 DNA reservoirs were derived from HIV-1 RNA variants
that had actively replicated during the last year(s) before
start of suppressive ART, with no evidence for evolution
after treatment start. Frenkel et al.[28], in contrast to us,
reported persistence of a greater number of early com-
pared to recent viruses in a few children on suppressive
ART; more research is warranted to assess the origin of
this difference.
Defective HIV-1 proviruses can be regarded as unique
in vivo labels of individual memory CD4 cell clones which
can be used to track their fate similar to sequencing of T-
cell receptors [29]. This strategy was used by Imamichi
et al.[30] to demonstrate that a T-cell clone persisted
6more than 17 years. Similarly, prenatally formed T-cell
receptors shared by twins have been reported to have
lifetimes > 30 years [31]. During suppressive ART the
turnover of infected memory CD4 cell clones is likely to
follow the same dynamics as in uninfected people. In
contrast, we observe a strong overrepresentation in the
reservoirs of “late” HIV-1 RNA variants, which indicates
that HIV-1 target cells, primarily CD4+ T-lymphocytes,
were turning over with a half-life of about one year in
absence of treatment. This turnover was dramatically
slowed by suppressive ART. Earlier studies, based on dif-
ferent types of labelling of CD4 cells, have indicated a 3 -
4 fold increased rate of CD4 cell death in untreated HIV-
1-infected patients as compared with uninfected persons
and patients on suppressive ART [32–34]. The more dra-
matic difference we observe is likely explained by different
methodologies. Earlier studies estimated the lifespan of
individual cells whereas we primarily have estimated the
lifespan of CD4 cell clones carrying defective proviruses
(i.e. infected cells as well as their daughter cells).
Our study has several limitations. We have not sorted
cells and therefore cannot investigate if there are differ-
ences in HIV-1 turnover between different types and sub-
sets of cells, such as memory CD4 cells and their subsets.
However, it is reasonable to assume that a majority of
our HIV-1 DNA sequences came from memory CD4 cells
because others have shown that these cells constitute the
main HIV-1 reservoir [1–3]. We sequenced a relatively
short region of the HIV-1 genome and therefore cannot
reliably distinguish between replication-competent and
defective viruses. While we observe no evolution in these
proviral DNA sequences, we cannot rule out the possibil-
ity that a small subset of viruses indeed was replicating
but remained undetected among the many replication-
incompetent viruses. We observed large variations in
the abundance of sequence haplotypes that likely reflect
both clonal expansions [5, 13], independent integrations
of identical sequences, and resampling of the same orig-
inal DNA templates during sequencing. With our se-
quencing method we could not exactly determine the rel-
ative contribution by these distinct mechanisms. We are
attempting Primer ID sequencing [35] to even better un-
derstand the in vivo dynamics of different viral haplo-
types.
In summary, we provide compelling evidence against
persistent viral replication as a mechanism to main-
tain the latent HIV-1 DNA reservoir during suppressive
therapy. Furthermore, we show that most latently in-
fected cells during long-term suppressive ART are in-
fected shortly before ART start and that the rate of T-cell
turnover is reduced upon starting suppressive ART.
Materials and methods
Ethical statement The study was conducted accord-
ing to the Declaration of Helsinki. Ethical approval was
granted by the Regional Ethical Review board in Stock-
holm, Sweden (Dnr 2012/505 and 2014/646). Patients
participating in the study gave written and oral informed
consent to participate.
Patients The study included 10 HIV-1-infected pa-
tients who were diagnosed in Sweden between 1990 and
2003. Prior to the present study the patients were in-
cluded in a recent study on the population genomics of
intrapatient HIV-1 evolution [26]. The patients were se-
lected based on the following inclusion criteria: 1) A rel-
atively well-defined time of infection based on a negative
HIV antibody test less than two years before a first pos-
itive test or a laboratory documented primary HIV in-
fection; 2) No ART during a minimum of approximately
five years following diagnosis; 3) Availability of biobank
plasma samples covering this time period; and 4) Later
have started successful ART (plasma viral levels < 50
copies/µl) for a minimum of two years. As previously
described 6 - 12 plasma samples per patient were re-
trieved from biobanks and used for full-genome HIV-1
RNA sequencing [26]. The same patient nomenclature is
used in both studies. For the present study the same pa-
tient were asked to donate 70 ml of fresh EDTA-treated
blood on up to three occasions over a time period of 2.5
years. These blood samples were obtained 3 - 18 years
after start of successful ART. Estimated time of infection
(ETI) was calculated as previously described using clini-
cal and laboratory findings including Fiebig staging and
BED testing [26]. Information about the patients and
the samples are summarized in Table 1.
HIV-1 RNA sequencing from plasma Whole-genome
deep-sequencing of virus RNA populations in plasma
samples obtained before start of therapy was performed
as previously described [26]. In short, total RNA in
plasma was extracted using RNeasy® Lipid Tissue Mini
Kit (Qiagen Cat No. 74804) and amplified using a one-
step RT-PCR with outer primers for six overlapping re-
gions and Superscript ® III One-Step RT-PCR with
Platinum ® Taq High Fidelity High Enzyme Mix (In-
vitrogen, Carlsbad, California, US). An optimized Illu-
mina Nextera XT library preparation protocol was used
together with a kit from the same supplier to build DNA
libraries, which were sequenced on the Illumina MiSeq
instrument with 2 x 250bp or 2x 300bp sequencing kits
(MS-102-2003/MS-10-3003). For the present study a
part of the p17gag region of the HIV-1 genome (see be-
low) was extracted from the entire full-genome RNA data
set. The median number of high quality reads covering
the entire p17 sequence was 146 (inter-quartile range 56
- 400) and the cDNA template numbers are available in
Zanini et al.[26].
HIV-1 DNA sequencing from PBMCs Approximately
70 ml of fresh whole blood was obtained in 7 Vacu-
tainer tubes with EDTA as anticoagulant. PMBC were
isolated by Ficoll-Paque PLUS (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) centrifugation according
to the instructions by the manufacturer. Total DNA was
extracted from PBMC using the OMEGA E.Z.N.A®
Blood DNA Mini Kit (Omega bio-tek, Norcross, Geor-
7gia) or the QIAamp DNA Blood Mini Kit (Qiagen
GmbH, Hilden, Germany) according to the instructions
by the manufacturer. The amount of DNA was mea-
sured with Qubit® dsDNA HS Assay Kit (Invitrogen™
Eugene, Oregon, USA). Patient-specific nested primers
(Integrated DNA Technologies) were used to amplify a
387-bp long portion of the p17gag gene corresponding to
positions 787 to 1173 in the HxB2 reference sequence.
The primers were designed based on the plasma RNA se-
quences from each patient (Tab. S2). Outer primers were
used together with Platinum® Taq DNA Polymerase
High Fidelity (Invitrogen™ Carlsbad, California, US) for
the first PCR. The program started with a denaturation
step at 94°C for 2 min followed by 15 PCR cycles of de-
naturation at 94°C for 20 s, annealing at 50°C for 20 s and
extension at 72°C for 30 s and a final extension step at
72°C for 6 min. For the second PCR, 2.5 µl of the product
from the first PCR was amplified with inner primers and
the cycle profile and enzyme as for the first PCR. Am-
plified DNA was purified using Agencourt AMPure XP
(Beckman Coulter Beverly, Massachusetts) and quanti-
fied using Qubit. For each sample the number of HIV-1
DNA templates used for sequencing was roughly quan-
tified in triplicate by limiting dilution using the same
PCR conditions, three dilutions (usually 0.5, 0.1, 0.02
µg of DNA) and Poisson statistics. Control experiments
were performed to evaluate PCR-induced recombination
using the plasmids NL4-3 and SF162, which were spiked
in equal proportion into human DNA and amplified using
the same PCR conditions as above. The results showed
that there was minimal PCR-induced recombination in
this short amplicon.
Sequencing and read processing The HIV specific
primers were flanked by NexteraXT adapters. To
construct sequencing libraries, indices and sequencing
primers were added in 12-15 cycles of additional PCR.
Amplicons were sequenced on an Illumina MiSeq machine
with 2x250 cycle kits. Between 6,500 and 190,000 (me-
dian 35,000) paired-end reads were generated per sam-
ple. The overlapping paired-end sequencing reads were
merged to create synthetic reads spanning the entire p17
amplicon. In case of disagreement between paired reads,
the nucleotide on the read with the higher quality score
was used. We counted the number of times a particular
p17 sequence was observed and did subsequent analysis
with read-abundance pairs. To reduce the influence of
sequencing and PCR errors, we combined rare sequences
(below frequency 0.002) with common sequences if they
differed by no more than one position. Specifically, start-
ing with the rarest sequences, we merged rare sequences
with the most common sequence that was one base away.
The cutoff 0.002 is the typical error frequency of the
pipeline as determined earlier [26]. All analysis is done in
Python using the libraries numpy, biopython, and mat-
plotlib [36–38].
Hypermutation detection To classify sequences into
obvious hypermutants and sequences representative of
circulating virus, we counted mutations at positions that
are not variable in the RNA samples obtained prior to
therapy. If more than 4 mutations were observed and at
least half of them were G→A, the sequence was considered
a hypermutant. The distribution of the different transi-
tion mutations relative to the closest genome found in
RNA samples are shown in Fig. S2 for reads classified as
hypermutants or not. Results we obtained for sequences
classified as non-hypermutants are very similar to results
obtained when using only sequences without stop codons.
Phylogenetic analysis We reconstructed phylogenetic
trees using the approximate maximum likelihood method
implemented by FastTree [27]. Tips were annotated with
frequency, source and sample date using custom python
scripts.
Statistical analysis Root-to-tip distances were calcu-
lated as the average distance between a sample and
the founder sequence approximated by the consensus se-
quence of the first RNA sample. To determine the rate
of evolution in absence of treatment, this root-to-tip dis-
tance was regressed against time. To determine the rate
of evolution on treatment, the root-to-tip sequence of the
last RNA sample and the DNA samples was regressed
against time. To determine the most likely seeding time
for a p17gag DNA sequence obtained from PBMCs, we
calculated the likelihood of sampling this sequence given
the SNP frequencies in each RNA sample and assigned
the sequence to the sample where this likelihood was
highest.
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Figure S1: Distributions of frequencies of haplotypes. We observe a wide variation of haplotype frequencies – measured by
fraction of reads – from below 0.001 to above 0.5. The majority of haplotypes are seen at frequencies around 0.01. Note that
both scales are logarithmic.
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Figure S2: Distributions of mutations classified as hypermutants or regular reads.
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Figure S3: Phylogenetic trees of RNA and DNA samples.
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Figure S4: Average root-to-tip distances for plasma HIV-1 RNA sequences obtained before start of ART and PBMC HIV-1
DNA sequences obtained after start of ART. This figure is analogous to Fig. 2 in the main text, but shows root-to-tip distance
of DNA sequences classified as hypermutants. While hypermutant sequences are between 2 and 4% more distance from the
approximate founder sequence, the distances do not change over time.
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